RA Capital Management PGNY Position
Active4-Fund ConvergenceRA Capital Management held their position in Progyny Inc. (PGNY) in Q4 2025, holding $2.5M worth of shares across 96,628 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
PGNY is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 10.9% of float with 3.8 days to cover, indicating significant bearish positioning against RA Capital's long thesis.
About Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Full company profile →Short Interest
10.9%
3.8 days to cover
RA Capital Management PGNY Position History
Frequently Asked Questions
Does RA Capital Management own PGNY?
Yes. As of Q4 2025, RA Capital Management holds 96,628 shares of Progyny Inc. (PGNY) valued at $2.5M. This data comes from their SEC 13F filing.
How many hedge funds own PGNY?
4 specialist biotech hedge funds currently hold PGNY, including OrbiMed Advisors, Redmile Group, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy PGNY?
RA Capital Management's position in PGNY was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's PGNY position increasing or decreasing?
RA Capital Management held their PGNY position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PGNYCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →